Depomed to Host Investor Day in New York City - RSVP Requested

MENLO PARK, Calif.--(Business Wire)--
Depomed, Inc. (NASDAQ:DEPO) announced today that it will be hosting an Investor
Day on Tuesday June 2, 2009 at the Marriott Marquis in New York City. The
meeting, which will also be webcast live, will begin at 11:00 a.m. Eastern Time
and end at 1:30 p.m. Eastern time. At the meeting, Depomed`s senior management
team will focus on the clinical development of SeradaTM for the treatment of
menopausal hot flashes. In addition, a leading expert on menopause education
will provide an overview of the menopausal hot flashes market and the
opportunity for Serada.

Institutional investors and analysts interested in attending the investor day
event can respond to DeDe Sheel via telephone at 1-415-293-4412 or e-mail at:
dede.sheel@fd.com.

Interested parties may listen to the live, audio webcast of the event by going
to the Company`s website at www.depomed.com and accessing the Investor Relations
section. A webcast replay will also be available via Depomed`s IR section on its
website immediately following the event.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved products
on the market and other product candidates in its pipeline. The company utilizes
its proven, proprietary AcuFormTM drug delivery technology to improve existing
oral medications, allowing for extended, controlled release of medications to
the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals
include the convenience of once-daily administration, improved treatment
tolerability and enhanced compliance and efficacy. GLUMETZA® (metformin
hydrochloride extended release tablets) is approved for use in adults with type
2 diabetes and promoted by Santarus, Inc. in the United States. Proquin® XR
(ciprofloxacin hydrochloride) is approved in the United States for the
once-daily treatment of uncomplicated urinary tract infections and is being
marketed in the United States within the urology, Ob/Gyn and long-term care
specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical
development for the treatment of neuropathic pain and has been licensed to
Solvay Pharmaceuticals. Product candidate Serada is in clinical development for
menopausal hot flashes. Additional information about Depomed may be found on its
website, www.depomed.com.

Depomed, Inc.
Sheilah Serradell, 650-462-5900
sserradell@depomed.com

Copyright Business Wire 2009